Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ULTRALIFE CORP (ULBI)
|
Add to portfolio |
|
|
|
| Price: |
$8.59
| | Metrics |
| OS: |
16.2
|
M
| |
|
|
| Market cap: |
$139
|
M
| |
|
|
|
Net debt:
|
$8.16
|
M
| |
|
|
|
EV:
|
$147
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 131.8 | 98.3 | 107.7 | 106.8 | 87.2 | 85.5 | 82.5 | 76.4 |
| Revenue growth | 34.2% | -8.8% | 0.9% | 22.5% | 1.9% | 3.7% | 7.9% | 14.9% |
| Cost of goods sold | 102.4 | 73.6 | 78.6 | 75.6 | 61.6 | 59.3 | 57.4 | 53.1 |
| Gross profit | 29.4 | 24.6 | 29.2 | 31.2 | 25.6 | 26.2 | 25.1 | 23.3 |
| Gross margin | 22.3% | 25.1% | 27.1% | 29.2% | 29.3% | 30.7% | 30.4% | 30.5% |
| Selling, general and administrative | 22.2 | 17.8 | 23.5 | 17.0 | 14.5 | 15.0 | 15.4 | 14.2 |
| Research and development | 7.1 | 6.8 | | 6.8 | 4.5 | 4.7 | 5.9 | 5.6 |
| EBITA | 1.4 | 0.7 | 9.4 | 7.9 | 7.0 | 6.9 | 4.3 | 3.7 |
| EBITA margin | 1.1% | 0.7% | 8.7% | 7.4% | 8.0% | 8.1% | 5.2% | 4.9% |
| Amortization of intangibles | 1.3 | 0.6 | 0.6 | 0.5 | 0.4 | 0.4 | 0.5 | 0.2 |
| EBIT | 0.1 | 0.0 | 8.8 | 7.4 | 6.6 | 6.5 | 3.8 | 3.5 |
| EBIT margin | 0.1% | 0.0% | 8.2% | 6.9% | 7.5% | 7.6% | 4.6% | 4.6% |
| Pre-tax income | -0.4 | -0.2 | 7.0 | 6.8 | 6.6 | 6.3 | 3.6 | 3.2 |
| Income taxes | -0.3 | 0.1 | 1.7 | 1.5 | -18.4 | -1.4 | 0.1 | 0.3 |
| Tax rate | 73.1% | | 24.1% | 21.5% | | | 2.7% | 9.8% |
| Net income | -0.1 | -0.2 | 5.2 | 5.2 | 24.9 | 7.6 | 3.5 | 2.9 |
| Net margin | -0.1% | -0.2% | 4.9% | 4.9% | 28.6% | 8.9% | 4.3% | 3.8% |
| |
| Diluted EPS | ($0.01) | ($0.01) | $0.33 | $321.71 | $1.53 | $0.48 | $0.23 | $0.17 |
| Shares outstanding (diluted) | 16.1 | 16.0 | 16.1 | 0.0 | 16.3 | 15.9 | 15.4 | 16.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|